Mylan N.V.

If you purchased Mylan N.V. securities and would like to join the action, please click "Join This Action" below.

MYLAN MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF MYLAN N.V. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – MYL

April 13, 2020.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. is fair to Mylan shareholders. On April 2, 2020, Morgan Stanley reportedly set a target price for Mylan at $18.00 per share. On behalf of Mylan shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

The Mylan merger investigation concerns whether Mylan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Mylan shareholders; and (2) disclose all material information necessary for Mylan shareholders to adequately assess and value the merger consideration.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Certification

Scroll to Top